Today: 16 July 2026
RELX PLC reiterates 2026 growth outlook as AI fears keep pressure on shares
6 March 2026
2 mins read

RELX PLC reiterates 2026 growth outlook as AI fears keep pressure on shares

London, March 6, 2026, 09:00 GMT

RELX PLC stuck to its 2026 growth targets in a March investor deck published Thursday, pointing to wider adoption of artificial intelligence in its product lineup as a driver for both customer value and profits. The latest update, posted after a tough stretch for legal and data names, keeps the FTSE 100 information company pressing its advantage.

The question hanging over RELX right now: will generative AI shore up the company’s businesses, or undercut them? The past month has seen investors wrestling with that. Back in early February, Reuters highlighted how Anthropic’s legal AI tools helped spark a wave of selling in RELX, along with Thomson Reuters and Wolters Kluwer. Yet Thursday saw RELX claw back 2.74%, ending the session at 2,623 pence. The FTSE 100 dropped 1.45%.

The slide deck stuck to RELX’s usual script, forecasting “another year of strong underlying growth” for both revenue and adjusted operating profit. Here, “underlying” backs out currency moves and select portfolio shifts. The deck confirmed 2025 revenue guidance at 9.59 billion pounds, with adjusted operating profit pinned at 3.342 billion pounds, and called for 10% constant-currency growth in adjusted earnings per share. Chief Executive Erik Engstrom pointed to AI, saying it’s set to be “a key driver of customer value and growth in our business for many years to come.” Relx

February’s numbers back up management’s favored narrative. Risk, the top division at RELX, delivered 2025 revenue of 3.485 billion pounds, notching 8% underlying growth. Legal climbed 9%, lifted by the likes of Lexis+ AI and Protégé—AI-powered offerings that drove robust renewals and fresh sales across major segments, according to the company.

RELX highlighted new product moves within its faster-growing segments. On March 5, LexisNexis Risk Solutions announced it’s bringing expanded identity verification tools to the Epic Connection Hub used by U.S. hospitals. Next up: adding IDVerse, an AI-driven system built to spot deepfakes, document forgeries, and other types of fraud.

“Striking a balance between user experience and security is critical in an industry that’s still a prime target for cybercrime,” Jonathan Shannon, AVP of healthcare strategy at LexisNexis Risk Solutions, said in the announcement. LexisNexis Risk Solutions

Not everyone’s convinced this rally makes sense. On March 5, Morningstar’s Rob Hales said, “We still view Thomson, RELX, and Wolters stock as undervalued,” and pointed to “heavy pessimism about the sector” already baked into current prices. Morningstar, Inc.

But the risk hasn’t disappeared. Reuters noted last month that Anthropic’s debut erased value from software and professional-services shares, and this week Goldman Sachs executive Mahesh Saireddy flagged that AI-related uncertainty is making lending decisions trickier. For RELX, the fundamental question lingers: can proprietary data and deeply integrated workflows defend pricing power, or will faster-moving, AI-native newcomers take the lead?

RELX hasn’t let up on cash returns as it continues to push its case. In February, the company outlined a 2.25 billion pound buyback for 2026, followed by a proposed final dividend of 48.0 pence per share. The annual meeting is set for April 23.

Thursday’s bounce didn’t close the gap—shares are still trading roughly 37% under their 52-week high. Investors remain unconvinced; RELX needs to show it can pivot the AI story from risk to real, lasting growth.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • AtaiBeckley (NASDAQ: ATAI) Soars 31% After Lilly $3.8B Buyout Bid
    July 16, 2026, 10:45 AM EDT. Shares of AtaiBeckley shot up 31% to $7.04 after Eli Lilly launched a $6.75-a-share cash bid, putting the deal value at up to $3.8 billion. Traders pushed the price $0.29 above the offer, betting on the $2.50 per share CVR tied to drug pipeline goals. About 80% of the CVR hinges on VLS-01, now in Phase 2b as a psychedelic treatment, with another 20% tied to BPL-003, which has FDA breakthrough status. The sale is expected to close in Q3, if it clears shareholder and regulatory hurdles. The market is treating most of the current price as cash and leaving some room for the CVR milestones, which still need regulatory and DEA signoffs.
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom
Previous Story

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

AppLovin Lands Stagwell Tie-Up as Mobile Gaming Ads Push Into Brand Budgets
Next Story

AppLovin Lands Stagwell Tie-Up as Mobile Gaming Ads Push Into Brand Budgets

Go toTop